Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pomaglumetad methionil

- PMLiVE

Lilly’s psoriasis candidate tops Enbrel in phase III trials

Ixekizumab on course for regulatory filing in first half of 2015

- PMLiVE

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

Full FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

- PMLiVE

Boehringer/Lilly’s Jardiance approved in US

But the FDA wants four post-marketing studies of the SGLT-2 diabetes drug

National Institute for Health and Care Excellence NICE logo

Lilly’s Efient and Sucampo’s Amitiza win NICE backing

Blood clot and constipation drugs recommended for NHS use

- PMLiVE

Lilly steps up cancer immunotherapy research

Agrees development deal with Immunocore

- PMLiVE

Otsuka and Lundbeck file Abilify follow-up in the US

Brexpiprazole to be reviewed for use in schizophrenia and major depressive disorder

Ashfield team picks up Lilly sales award

Syndicated pharma sales team rewarded with supplier prize

- PMLiVE

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

- PMLiVE

Destination Discovery – Lilly’s answer to Boehringer’s Syrum?

Lilly launches online drug discovery game

- PMLiVE

ADA: Empagliflozin overcomes FDA concerns

Boehringer and Lilly expect decision on diabetes treatment by end of 2014

- PMLiVE

ADA: Lilly/Boehringer insulin glargine matches Lantus

Biosimilar demonstrates equal efficacy to Sanofi’s big-selling diabetes treatment

- PMLiVE

Lilly launches depression information app

iPhone and Android app Talking Progress aims to strengthen patient-HCP communication

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links